Quebec-based Merck Canada today announced Health Canada approved an expanded indication of GARDASIL®9 in individuals 9 through 45 years of age to prevent infection caused by the Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
And this approval is for Oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
It is estimated that more than 550,000 Canadians become infected with HPV each year.
